Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Ozempic is changing more than just waistlines; it is also altering dining habits across the United States. Medical professionals and recent surveys reveal intriguing shifts in how Americans eat out.
According to a recent Bloomberg Intelligence report, individuals using GLP-1 medications like Ozempic and Wegovy are significantly adjusting their spending on dining out and takeout. This data shows that 54% of the 1,000 surveyed GLP-1 users reported dining out less frequently since starting treatment. A comparable percentage is also cutting back on takeout meals.
Increased home cooking is a notable trend, with 70% of respondents indicating a rise in home-cooked meals since beginning their GLP-1 regimen. This aligns with a broader cultural shift towards healthy eating as awareness grows about the impact of obesity on health.
GLP-1 agonists, such as Ozempic, originally designed for type 2 diabetes management, assist in regulating blood sugar levels. These medications slow digestion and suppress appetite, prompting users to consume smaller portions or focus on nutritious meals. As a result, traditional restaurant dining presents new challenges for many.
Approximately 4% of American adults, about one in 25, are currently prescribed a GLP-1 drug for weight loss or the management of type 2 diabetes. This growing popularity has led to an astonishing 600% increase in prescriptions specifically for weight management.
Dr. Fernando Ovalle Jr., an obesity medicine expert based in Florida, shares insights from his patients. He notes that many users find once-familiar restaurant portions to now be overwhelming.
“Patients consistently inform me that they can barely finish a third of their order, making dining out feel wasteful and costly,” said Ovalle in an interview.
Beyond changes in portion size, users also report a decreased desire for calorie-rich foods such as fried items, sugary sauces, and desserts. Instead, many individuals are opting for shared entrées, omitting appetizers, and forgoing high-calorie drinks.
While anecdotal evidence suggests that GLP-1 medications may impact alcohol consumption, further research is ongoing. Novo Nordisk, the pharmaceutical company behind these drugs, has launched a phase 2 clinical trial examining the influence of semaglutide, an active ingredient in both Wegovy and Ozempic, on alcohol-related liver disease, with drinking patterns being monitored as a secondary measurement.
A Morgan Stanley report also highlighted that 63% of GLP-1 users reported ordering less when dining out. This trend could suggest that restaurants need to adapt their offerings to stay relevant.
Dr. Ovalle reiterates the changing preferences of his patients. They increasingly favor dishes rich in protein and vegetables, steering clear of high-sugar and high-fat options.
Restaurants are responding to this new clientele by modifying their menus. Options featuring smaller portions, nutrient-dense fare, and more transparency about nutritional content are becoming common. Dr. Ovalle emphasizes that smaller appetites do not necessarily translate into reduced business for restaurants. Instead, those that adapt their menus may thrive in this evolving dining landscape.
In New York City, the restaurant Tucci has begun serving reduced sizes of Italian staples like meatballs and arancini. Owner Max Tucci reveals that customers openly discuss their use of Ozempic when ordering smaller portions.
“Customers are not hesitant to ask, ‘I’m on Ozempic; do you have smaller portions?'” Tucci explained during a recent interview.
The transformation in American dining habits arises from various influences. Gen Z customers, for instance, tend to split appetizers and often skip alcohol altogether as a way to economize.
Recent data from the e-commerce platform Lightspeed indicates a surprising trend among adults, with nearly half reportedly ordering from the children’s menu for themselves. This behavior is driven by preferences for smaller portions, simpler meals, and more cost-effective choices.
The decline in dining out is impacting people across all income brackets and could be exacerbated by additional factors such as labor shortages and uncertainty surrounding tariffs.
Novo Nordisk’s representatives did not comment on the potential effects of their drugs on dining patterns. However, they affirmed the strong clinical evidence supporting the effectiveness of semaglutide in enhancing health outcomes for individuals facing obesity or other weight-related challenges.
The spokesperson highlighted the significance of their work in advancing treatment options, stating, “We are proud of the advancements in our drugs, which have already changed the lives of many individuals suffering from chronic diseases, including diabetes and obesity.”
They added, “It is gratifying to witness how Ozempic and Wegovy have positively affected so many lives across America.”
As dining habits continue to evolve thanks to medications like Ozempic, both users and restaurants are adapting. Understanding these trends may lead to a restaurant industry’s renaissance, catering thoughtfully to the needs of a new generation of diners.
